Baker Avenue Asset Management’s Novavax NVAX Stock Holding History

Baker Avenue Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-59	Closed	-$438	–	1676
2023 Q2	$438	Buy	+59	New	+$464	﹤0.01%	1462

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Baker Avenue Asset Management's NVAX Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Novavax (NVAX) in Q3 2023, closing a stake of 59 shares — an estimated $438 sold.

Baker Avenue Asset Management first reported a position in NVAX in Q2 2023 and held it in 1 quarter. The position peaked at $438 in Q2 2023. 225 funds tracked by Wall St. Rank hold NVAX as of Q3 2023.

Baker Avenue Asset Management reported no remaining Novavax position as of Q3 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 59 Novavax shares in Q3 2023, an estimated $438.
Baker Avenue Asset Management first reported a position in Novavax in Q2 2023 and held it in 1 quarter.
Baker Avenue Asset Management's Novavax position peaked at $438 in Q2 2023.
225 funds tracked by Wall St. Rank held Novavax as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.